UroGen Pharma Ltd
URGN
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.64B
Close$
$-30.56
186.9% downside
Current Fair Value
186.9% downsideOvervalued by 186.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.64 Billion |
|---|---|
| Enterprise Value | $1.73 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.19 |
| Beta | 1.62 |
| Outstanding Shares | 50,182,758 |
Return
| Return on Equity | 107.22% |
|---|---|
| Return on Assets | -52.51% |
| Return on Invested Capital | -55.46% |
Valuation & Multiples
| P/E Ratio | -12.65 |
|---|---|
| PEG | 27.35 |
| Price to Sales | 17.58 |
| Price to Book Ratio | -11.72 |
| Enterprise Value to Revenue | 12.31 |
| Enterprise Value to EBIT | -15.36 |
| Enterprise Value to Net Income | -13 |
| Total Debt to Enterprise | 0.12 |
| Debt to Equity | -1.65 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 11, 2026
EPS Estimate
$-0.48
Average shareholder expectationRevenue Estimate
$44.83 M
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-0.30
Average shareholder expectationRevenue Estimate
$61.60 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.7613▲ 60.73% |
|---|---|
| Total Calls | 226,200▼ 83.42% |
| Total Puts | 172,200▼ 18.04% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 94.29%▲ 3.34% |
|---|---|
| Total Invested | $834.80M▼ 18.44% |
| Investors Holding | 178▲ 2.00% |
ESG Score
No data
About UroGen Pharma Ltd
CEO: Elizabeth Barrett